A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Study Purpose

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

- The patient is ≥18 years of age at observational point 1 - The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice - The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care - The patient must be newly prescribed with certolizumab pegol - If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study

Exclusion Criteria:

Not applicable

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04053881
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

UCB Biopharma S.P.R.L.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

UCB Cares
Principal Investigator Affiliation 001 844 599 2273 (UCB)
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Belgium, Canada, Czechia, Germany, Spain, United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Plaque Psoriasis
Arms & Interventions

Arms

: Certolizumab pegol

Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).

Interventions

Drug: - Certolizumab pegol

Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Ps0026 107, Brussels, Belgium

Status

Recruiting

Address

Ps0026 107

Brussels, ,

Ps0026 101, Bruxelles, Belgium

Status

Recruiting

Address

Ps0026 101

Bruxelles, ,

Ps0026 103, Bruxelles, Belgium

Status

Recruiting

Address

Ps0026 103

Bruxelles, ,

Ps0026 108, Lede, Belgium

Status

Recruiting

Address

Ps0026 108

Lede, ,

Ps0026 102, Leuven, Belgium

Status

Recruiting

Address

Ps0026 102

Leuven, ,

Ps0026 110, Maldegem, Belgium

Status

Recruiting

Address

Ps0026 110

Maldegem, ,

Ps0026 109, Mons, Belgium

Status

Recruiting

Address

Ps0026 109

Mons, ,

Ps0026 104, Namur, Belgium

Status

Recruiting

Address

Ps0026 104

Namur, ,

Ps0026 208, London, Canada

Status

Recruiting

Address

Ps0026 208

London, ,

Ps0026 209, London, Canada

Status

Recruiting

Address

Ps0026 209

London, ,

Ps0026 201, Markham, Canada

Status

Recruiting

Address

Ps0026 201

Markham, ,

Ps0026 210, Newmarket, Canada

Status

Recruiting

Address

Ps0026 210

Newmarket, ,

Ps0026 205, Waterloo, Canada

Status

Recruiting

Address

Ps0026 205

Waterloo, ,

Ps0026 301, Praha, Czechia

Status

Recruiting

Address

Ps0026 301

Praha, ,

Ps0026 303, Praha, Czechia

Status

Recruiting

Address

Ps0026 303

Praha, ,

Ps0026 302, Uherské Hradiště, Czechia

Status

Recruiting

Address

Ps0026 302

Uherské Hradiště, ,

Ps0026 503, Bergen auf Rügen, Germany

Status

Recruiting

Address

Ps0026 503

Bergen auf Rügen, ,

Ps0026 512, Bielefeld, Germany

Status

Recruiting

Address

Ps0026 512

Bielefeld, ,

Ps0026 525, Dresden, Germany

Status

Recruiting

Address

Ps0026 525

Dresden, ,

Ps0026 506, Düren, Germany

Status

Recruiting

Address

Ps0026 506

Düren, ,

Ps0026 523, Hamburg, Germany

Status

Recruiting

Address

Ps0026 523

Hamburg, ,

Ps0026 518, Karlsruhe, Germany

Status

Recruiting

Address

Ps0026 518

Karlsruhe, ,

Ps0026 508, Langenau, Germany

Status

Recruiting

Address

Ps0026 508

Langenau, ,

Ps0026 519, Leipzig, Germany

Status

Recruiting

Address

Ps0026 519

Leipzig, ,

Ps0026 516, Merzig, Germany

Status

Recruiting

Address

Ps0026 516

Merzig, ,

Ps0026 517, München, Germany

Status

Recruiting

Address

Ps0026 517

München, ,

Ps0026 515, Nürnberg, Germany

Status

Recruiting

Address

Ps0026 515

Nürnberg, ,

Ps0026 501, Potsdam, Germany

Status

Recruiting

Address

Ps0026 501

Potsdam, ,

Ps0026 511, Quedlinburg, Germany

Status

Recruiting

Address

Ps0026 511

Quedlinburg, ,

Ps0026 505, Remscheid, Germany

Status

Recruiting

Address

Ps0026 505

Remscheid, ,

Ps0026 804, Pontevedra, Spain

Status

Recruiting

Address

Ps0026 804

Pontevedra, ,

Ps0026 901, Salford, United Kingdom

Status

Recruiting

Address

Ps0026 901

Salford, ,

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.